Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003956 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy in Treating Patients With Advanced Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00003956: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00003956 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003956, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of SCH 66336, fluorouracil, and leucovorin in treating patients who have advanced cancer.
Interventions
- DRUG fluorouracil
- DRUG leucovorin calcium
- DRUG lonafarnib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 1999-04 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003956
The ClinicalTrials.gov registry entry for NCT00003956 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which fluorouracil is the first listed.
NCT00003956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003956 about?
NCT00003956 is a clinical study titled "Combination Chemotherapy in Treating Patients With Advanced Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of SCH 66336, fluorouracil, and leucovorin in treating patients who hav...
What is the current status of trial NCT00003956?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 1999-04. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00003956?
The interventions under investigation include: fluorouracil (DRUG), leucovorin calcium (DRUG), lonafarnib (DRUG).
Who is sponsoring clinical trial NCT00003956?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.